Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.
She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on LinkedIn.
People With MS Face Higher Rates of Harassment, Criticism at Work Than Healthy Employees
September 24th 2020Patients with multiple sclerosis (MS) reported higher rates of harassment and criticism in the workplace than their healthy counterparts, even after informing employers and coworkers about their diagnosis.
Read More
Study: Muscle Loss May Lead to Higher Mortality and Costs for Patients Hospitalized for COPD
August 8th 2020A new study has found that muscle loss can lead to increased rates of mortality and morbidity in patients with chronic obstructive pulmonary disease (COPD). However, one expert remains skeptical whether the study represents the full scope of patients at risk.
Read More
Light Exercise May Cut Exacerbations, Hospital Readmissions in AECOPD
August 1st 2020A shorter course of pulmonary rehabilitation, with phone support, improved symptoms and reduced hospital readmissions for patients with post-acute exacerbation in chronic obstructive pulmonary disease (AECOPD).
Read More
Supplemental Process Can Aid in Assessing Value of Rare Disease Treatments
July 25th 2020A study looking at the ways in which different countries handle appraisal and reimbursement processes for rare disease treatments (RDTs) revealed that implementing supplemental processes can aid in patient and physician decision making.
Read More
Social Media May Benefit Patients With MS-Associated Depression
July 19th 2020By delivering helpful information and fostering online communities, social media may provide rehabilitation and psychological benefits for patients with multiple sclerosis (MS) who have depression, according to the results of a recent Iranian study.
Read More
Gaps Remain Between European Regions for Hemophilia Care Despite Improvements
July 17th 2020Hemophilia care principles have been on the rise in Europe over the course of the last decade, however, differing regions and policies on the continent reveal gaps in access to various treatments and specialty services.
Read More
Review Calls For Clear Guidance to Ensure Patient Centricity in Orphan Drug Trials
July 12th 2020Researchers called for new guidance to address the underreporting of patient engagement in rare disease clinical trials after finding a dismal amount of patient-reported outcome measures listed in orphan drug labeling claims.
Read More
Authors Call for More Research on Rare Blood Cancers to Fill Knowledge Gaps
July 4th 2020Authors hope that identifying knowledge gaps surrounding rare blood cancers, such as essential thrombocythemia and polycythemia vera, will inspire the science community to invest in new comprehensive research on how to properly diagnose and treat patients.
Read More
Combination Therapy More Effective Than Standard Treatment for Rare Blood Disease
June 16th 2020A study conducted by Mayo Clinic researchers revealed that a combined treatment featuring daratumumab in conjunction with the standard-of-care for patients with amyloid light-chain (AL) amyloidosis was more effective in improving the condition than the standard treatment alone.
Read More
Immunosuppressive Psoriatic Drugs Don't Increase Risks for COVID-19 Complications
June 13th 2020Authors of an opinion piece concluded that not only are immunosuppressed patients with psoriasis not at an increased risk of developing serious complications related to coronavirus disease 2019 (COVID-19), their medications may help mitigate potential issues.
Read More
Orphan Drug Reimbursements Create Tough Situation for South Korean Public Budget
June 12th 2020A data analysis of real-world data found that the rise of orphan drugs (ODs) in the Republic of Korea has not solved all patient accessibility issues as budget concerns can make it difficult to justify reimbursements.
Read More
Ruxolitinib was found to be more cost-effective than the best available therapy (BAT) when the willingness-to-pay threshold for payers was at $150,000 and applied to patients with hydroxyurea resistant/intolerant polycythemia vera (PV) without splenomegaly, according to a new study.
Read More
Sociodemographic Factors Influence Outcomes Among Patients With Psoriasis
May 22nd 2020A patient’s sex, disease duration, and residence were the most common sociodemographic factors shown to affect illness acceptance, life satisfaction, sense of stigmatization, and quality of life among those who have psoriasis, according to the results of a recent study.
Read More